[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349102-105":59,"doc-detail-349102-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-covalent-allosteric-molecular-glue-suppresses-nrf2-dependent-cancer-growth-abstract","A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth - abstract","","The NRF2 transcription factor is constitutively active in many cancers, supporting oxidative homeostasis and metabolic reprogramming, while driving resistance to chemotherapy and radiotherapy. This study describes VVD-065, a first-in-class NRF2 inhibitor that uses an allosteric molecular glue mechanism by covalently engaging Cys151 on KEAP1. The resulting promotion of KEAP1–CUL3 complex formation enhances NRF2 degradation. VVD-065 suppresses NRF2-dependent tumor growth and sensitizes cancers to chemotherapy/RT, supporting clinical evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-covalent-allosteric-molecular-glue-suppresses-nrf2-dependent-cancer-growth-abstract/349102/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-covalent-allosteric-molecular-glue-suppresses-nrf2-dependent-cancer-growth-abstract/349102.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does NRF2 play in cancer progression?","Question",{"text":112,"@type":113},"NRF2 maintains oxidative homeostasis and reprograms cellular metabolism, enabling NRF2-active tumors to resist chemotherapy and radiotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does VVD-065 inhibit NRF2?",{"text":117,"@type":113},"VVD-065 covalently engages Cys151 on KEAP1, promoting KEAP1–CUL3 complex formation and enhancing NRF2 degradation via ubiquitin-mediated turnover.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic effects were observed with VVD-065?",{"text":121,"@type":113},"VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemotherapy/RT, supporting an open phase I clinical trial.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349102,1790874117,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ReseaRch aRticle  \nA Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer  \nGrowth   \nNilotpal Roy1, Tine Wyseure1, I-Chung Lo2, Justine Lu1, Christie L. Eissler1, Steffen M. Bernard1,  \nIlah Bok3, Aaron N. Snead1, Albert Parker1, U-Ging Lo1, Jason C. Green1, Jordon Inloes1, Sarah R. Jacinto1, Brent Kuenzi1, Marie Pariollaud1, Kathleen Negri1, Khoi Le1, Benjamin D. Horning1, Noah Ibrahim1, Stephanie Grabow1, Harit Panda4, Dhaval P. Bhatt3, Emily M. Wilkerson3, Soma Saeidi3, Paul Zolkind4, Zoe Rush1, Heather N. Williams1, Eric Walton1, Martha K. Pastuszka1, John J. Sigler1, Eileen Tran1, Kenneth Hee5, Joseph McLaughlin1, Géza Ambrus-Aikelin6, Jonathan Pollock1, Robert T. Abraham7, Todd M. Kinsella8, Gabriel M. Simon1, Michael B. Major3,4, David S. Weinstein1, and Matthew P. Patricelli1  \nThe NRF2 transcription factor is constitutively active in cancer, in which it functions to maintain oxidative homeostasis and reprogram cellular metabolism.  \nNRF2-active tumors exhibit NRF2 dependency and resistance to chemotherapy/radiotherapy (RT) . In this study, we characterize VVD-065, a first-in-class NRF2 inhibitor that acts via an unprecedented allosteric molecular glue mechanism. In the absence of stress or mutation, NRF2 is rapidly degraded by the Kelch-like ECH-associated protein 1 (KEAP1)–cullin3 (CUL3) ubiquitin-ligase complex. VVD-065 specifically and covalently engages Cys151 on KEAP1, which in turn promotes KEAP1–CUL3 complex formation, leading to enhancement of NRF2 degradation. Previously reported Cys151-directed compounds decrease KEAP1–CUL3 interactions and stabilize NRF2, thus establishing KEAP1C151 as a tunable regulator of the KEAP1–CUL3 complex and NRF2 stability. VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemotherapy/RT, supporting an open phase I clinical trial (NCT05954312) .  \nSiGNiFiCANCe: NRF2 hyperactivation is frequently observed in various solid tumors, including lung, esophageal, and head and neck cancers, highlighting NRF2 as a potential therapeutic target. We report a first-in-class KEAP1-dependent allosteric molecular glue degrader of NRF2, which demonstrated robust monotherapy responses in NRF2-activated cancers and effectively sensitized chemo-refractory tumors to chemotherapy.  \nSee related commentary by Hintzen and Burslem, p. 829  \nintRoduction  \nThe NRF2 transcription factor (encoded by the NFE2L2 gene) functions as a primary cellular defense against oxidative and electrophilic stress (1, 2) . In the absence of cellular stress, NRF2 expression is restricted at the protein level by the Kelch-like ECH-associated protein 1 (KEAP1) and cullin 3 (CUL3) E3-ubiquitin ligase complex. KEAP1 functions asthe substrate adapter protein on the CUL3 scaffold, directly binding and positioning NRF2 for ubiquitylation. Hundreds of cellular stressors, including reactive oxygen species and electrophilic xenobiotics, lipids, and metabolites, inactivate KEAP1–CUL3–mediated NRF2 degradation. Accumulated NRF2 protein then enters the nucleus to activate the transcription of ∼300 cytoprotective genes. Reactive cysteine residues in KEAP1 sense electrophilic stress, but precisely how this alters KEAP1 function to suppress NRF2 degradation is poorly understood (3, 4) .  \n1Vividion Therapeutics, San Diego, California. 2Degron Therapeutics, San Diego, California. 3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri. 4Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri. 5Sciex, Carlsbad, California. 6Genesis Therapeutics, San Diego, California. 7Engine Biosciences, Redwood City, California. 8Expedition Medicines, Cambridge, Massachusetts.  \nCorresponding Author: Matthew P. Patricelli, Vividion Therapeutics, 10075  \nBarnes Canyon Rd, San Diego, [CA 92121. E-mail: mattp@vividion.com](CA 92121. E-mail: mattp@vividion.com)  \nCancer Discov 2026;16:953–75  \ndoi: 10. 1158/2159-8290 . CD-25-1187  \nThis op","cbCaicTS8O5xraPo","https://ap.wps.com/l/cbCaicTS8O5xraPo","pdf",10010570,23,"English","# Introduction\n## NRF2 regulation and stress sensing\n## Therapeutic rationale for NRF2 inhibition\n# Study overview\n## VVD-065 mechanism and KEAP1 Cys151 engagement\n## Effects on NRF2 degradation and tumor response","[{\"question\":\"What role does NRF2 play in cancer progression?\",\"answer\":\"NRF2 maintains oxidative homeostasis and reprograms cellular metabolism, enabling NRF2-active tumors to resist chemotherapy and radiotherapy.\"},{\"question\":\"How does VVD-065 inhibit NRF2?\",\"answer\":\"VVD-065 covalently engages Cys151 on KEAP1, promoting KEAP1–CUL3 complex formation and enhancing NRF2 degradation via ubiquitin-mediated turnover.\"},{\"question\":\"What therapeutic effects were observed with VVD-065?\",\"answer\":\"VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemotherapy/RT, supporting an open phase I clinical trial.\"}]","A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth - abstract | PDF",1790081649,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/125d063e6ed16803f5205e7dbabe4d7a.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45524c9b2f2639634981740477445f6b.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/daa7f44c7b46b429520db6b065673da9.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc42b4e9d6f64c553090fa34ef66ce76.webp",980,1311]